In a filing, DermTech Inc. revealed its Chief Commercial Officer Wood Todd Michael unloaded Company’s shares for reported $1804.0 on Jun 13. In the deal valued at $4.81 per share,375 shares were sold. As a result of this transaction, Wood Todd Michael now holds 216,064 shares worth roughly $ 1.1 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Ibarra Claudia sold 345 shares, generating $1,659 in total proceeds. Upon selling the shares at $4.81, the Chief Operating Officer now owns 163,682 shares.
Before that, Wood Todd Michael sold 433 shares. DermTech Inc. shares valued at $2,711 were divested by the Chief Commercial Officer at a price of $6.26 per share. As a result of the transaction, Wood Todd Michael now holds 216,439 shares, worth roughly $1.1 million.
In the meantime, BTIG Research reiterated its DermTech Inc. [DMTK] rating to a Buy in a research note published on Tuesday, June 14, 2022; the price target was $19. PT values the company’s stock at a premium of 73.21 to its Tuesday closing price. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. BTIG Research started covering the stock on May 03, 2021. It rated DMTK as “a Buy”.
Price Performance Review of DMTK
On Tuesday, DermTech Inc. [NASDAQ:DMTK] saw its stock jump 6.04% to $5.09. On the same session, the stock had its day’s lowest price of $4.77, but rose to a high of $5.245. Over the last five days, the stock has gained 7.61%. DermTech Inc. shares have fallen nearly -67.78% since the year began. Nevertheless, the stocks have fallen -88.11% over the past one year. While a 52-week high of $48.32 was reached on 01/03/22, a 52-week low of $4.18 was recorded on 06/16/22. SMA at 50 days reached $7.86, while 200 days put it at $17.48. A total of 1.08 million shares were traded, compared to the trading of 1.33 million shares in the previous session.
Levels Of Support And Resistance For DMTK Stock
The 24-hour chart illustrates a support level at 4.83, which if violated will result in even more drops to 4.56. On the upside, there is a resistance level at 5.30. A further resistance level may holdings at 5.51. The Relative Strength Index (RSI) on the 14-day chart is 38.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.63%. Stochastics %K at 24.69% indicates the stock is a holding.
DermTech Inc. [DMTK] – Who Are The Largest Shareholders?
In filings from RTW Investments LP, it is revealed that the company now owns 3,118,666 shares, or roughly 10.42% of the outstanding DMTK shares. In other words, the investor’s shares have fallen by 0 from its previous 13-F filing of 3118666.0. Additionally, SSgA Funds Management, Inc. increased 7.93% of its stake after which the total value it holdings stand at $20,391,805, while Casdin Capital LLC reduced 0.00% of its stake to hold $11.59 million in the firm. Over the last quarter, BlackRock Fund Advisors sold 38 shares of DermTech Inc., while UBS O’Connor LLC sold 191,844 shares. At present, The Vanguard Group, Inc. is holding 1,226,429 shares valued at $8.14 million. Victory Capital Management, Inc. owned 1,141,004 shares of the company at the time of its most recent 13F filing, worth $7.58 million.
According to FactSet, DermTech Inc.’s share price will average $29.67 in the next year, based on opinions of analysts polled by the firm. This is up nearly 462.5 percent from its previous closing price of $4.80. Analysts expect DermTech Inc. stock to reach the higher price of $48.00, while the lowest price estimate is $19.00. However, 7 analysts have rated DMTK stock as a Buy in their predictions for 2022. The most recent change occurred on January 22, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $53 price target.